ESC-HFA 2024: Late-Breaking Science Video Collection

Published: 14 May 2024

  • Views:

    Views Icon 1067

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Association’s annual congress, Heart Failure 2024. 

Dive deep into novel data with in-depth and critical discussions led by Late-breaker host Dr Harriette Van Spall and her expert guests. 

For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators.

More from this programme

Part 1

Late-breaker Discussions with Dr Van Spall

Thought-provoking discussions with the investigators.
4 sessions
HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie Watch now
Late-Breaker Discussion: The TITRATE-HF Study Watch now
Late-Breaker Discussion: Insights from the STEP-HFpEF Watch now
Late-Breaker Discussion: Findings from PACT-HF Watch now

Part 2

Expert Interviews

Short, practical interviews with the investigators.
8 sessions
Remote Patient Monitoring for Patients With Heart Failure: TELESAT Watch now
Cordella PA Sensor System in NYHA Class III HF Patients: PROACTIVE-HF Watch now
Aspirin Avoidance after Implantation of a Fully Magnetically Levitated LVAD: ARIES HM3 Watch now
Timing of Cardio-Kidney Protection with SGLT2i Watch now
Treatment Benefit Consistency of Remote Hemodynamic Monitoring in CHF: MONITOR-HF Subgroup Analysis Watch now
Inter-Atrial Shunt Treatment to Reduce Lung Congestion in Patients with Advanced Heart Failure: RELIEVE-HF Watch now
FINE-HEART: Design & Baseline Characteristics Watch now
HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device Watch now

About the episode

HFA 24 - We are joined onsite by Dr Michael Kiernan (Tufts University School of Medicine, US) to discuss the findings from the PROACTIVE-HF Trial.

PROACTIVE-HF is a prospective, multicenter, open-label single arm trial which aimed to assess the device safety and efficacy of the Cordella Pulmonary Artery Sensor System in a population of 529 New-York Heart Association (NYHA) class III heart failure patients. The Cordella device is a novel system for monitoring ambulatory pulmonary artery pressure. The device comes packaged with a broader range of home disease management monitoring systems, including access to vital signs including weight, blood pressure and heart rate.

Key findings showed that the Cordella system was safe in regard to freedom from device implant complications and sensor failure (<1%). The device was also found to be effective in regard to event rates.

Interview Questions:

  1. What are the unmet needs of NYHA Class III Patients?
  2. Could you tell us more about the Cordella sensor system?
  3. What is the patient population and study design?
  4. What are your key findings?
  5. What are your take-home messages?
  6. What further study is needed?

Recorded on-site at HFA 2024, Lisbon.
Support: This is an independent interview conducted by Radcliffe Cardiology.

Editor: Jordan Rance

Videographer: Tom Green, Oliver Miles

Faculty Biographies

Michael Kiernan

View full profile

Comments

You must be to comment. If you are not registered, you can register here.